FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141338701> ?p ?o ?g. }

• W2141338701 endingPage "295" @default.
• W2141338701 startingPage "285" @default.
• W2141338701 abstract "Objective: To evaluate the pharmacology, pharmacokinetics, clinical efficacy, and tolerability of rotigotine, a nonergoline D 3 /D 2 /D 1 dopamine receptor agonist in the treatment of Parkinson's disease and restless legs syndrome (RLS). Data Sources: A literature search was conducted using MEDLINE (1996–December 2006) and International Pharmaceutical Abstracts, using the search terms rotigotine and dopamine agonist. References cited in the articles were reviewed for additional information. Information was also obtained from Schwarz Pharma. Abstracts for posters at scientific conferences were accessed from conference Web sites. Study Selection and Data Extraction: English-language literature reporting controlled animal and human clinical studies was reviewed to evaluate the pharmacology, pharmacokinetics, therapeutic use, and adverse effects of rotigotine. Clinical trials selected for inclusion were limited to those with human subjects; data from animal studies were included if human data were not available. Data Synthesis: Rotigotine has been investigated in early Parkinson's disease, as adjuvant therapy to levodopa in advanced Parkinson's disease, and in RLS. It is administered transdermally, which provides the convenience of once-daily dosing, constant drug delivery, and sustained stable plasma concentrations. In clinical trials of patients with early Parkinson's disease, rotigotine has decreased combined scores on the motor and activities of daily living sections of the Unified Parkinson's Disease Rating Scale up to 85 weeks. In patients with advanced Parkinson's disease, rotigotine reduced mean off-time when used as an adjuvant to levodopa. Rotigotine has decreased the severity of RLS in Phase III trials. Acute adverse events are similar to those of other dopamine agonists and are most common during the titration phase. Mild-to-moderate application site reactions are common. Conclusions: Longer trials are required to determine whether transdermal rotigotine will reduce development of dyskinesias and motor fluctuations in Parkinson's disease and augmentation and rebound in RLS by preventing pulsatile dopamine stimulation associated with levodopa and other dopamine agonists." @default.
• W2141338701 created "2016-06-24" @default.
• W2141338701 creator A5087323113 @default.
• W2141338701 date "2007-02-01" @default.
• W2141338701 modified "2023-09-25" @default.
• W2141338701 title "Rotigotine: Transdermal Dopamine Agonist Treatment of Parkinson's Disease and Restless Legs Syndrome" @default.
• W2141338701 cites W1968104857 @default.
• W2141338701 cites W1971932871 @default.
• W2141338701 cites W1977307550 @default.
• W2141338701 cites W1981821582 @default.
• W2141338701 cites W2010478064 @default.
• W2141338701 cites W2011753092 @default.
• W2141338701 cites W2016954422 @default.
• W2141338701 cites W2028849336 @default.
• W2141338701 cites W2029632110 @default.
• W2141338701 cites W2038975617 @default.
• W2141338701 cites W2069947800 @default.
• W2141338701 cites W2071419048 @default.
• W2141338701 cites W2080091650 @default.
• W2141338701 cites W2086622920 @default.
• W2141338701 cites W2095154425 @default.
• W2141338701 cites W2103964804 @default.
• W2141338701 cites W2113057210 @default.
• W2141338701 cites W2126303471 @default.
• W2141338701 cites W2130696280 @default.
• W2141338701 cites W2322912881 @default.
• W2141338701 cites W4239875825 @default.
• W2141338701 cites W4252472226 @default.
• W2141338701 cites W83552848 @default.
• W2141338701 doi "https://doi.org/10.1345/aph.1h113" @default.
• W2141338701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17213296" @default.
• W2141338701 hasPublicationYear "2007" @default.
• W2141338701 type Work @default.
• W2141338701 sameAs 2141338701 @default.
• W2141338701 citedByCount "62" @default.
• W2141338701 countsByYear W21413387012012 @default.
• W2141338701 countsByYear W21413387012014 @default.
• W2141338701 countsByYear W21413387012016 @default.
• W2141338701 countsByYear W21413387012017 @default.
• W2141338701 countsByYear W21413387012018 @default.
• W2141338701 countsByYear W21413387012020 @default.
• W2141338701 countsByYear W21413387012021 @default.
• W2141338701 countsByYear W21413387012023 @default.
• W2141338701 crossrefType "journal-article" @default.
• W2141338701 hasAuthorship W2141338701A5087323113 @default.
• W2141338701 hasConcept C126322002 @default.
• W2141338701 hasConcept C137183658 @default.
• W2141338701 hasConcept C197934379 @default.
• W2141338701 hasConcept C2776750294 @default.
• W2141338701 hasConcept C2778258207 @default.
• W2141338701 hasConcept C2778375690 @default.
• W2141338701 hasConcept C2779134260 @default.
• W2141338701 hasConcept C2779424955 @default.
• W2141338701 hasConcept C2779734285 @default.
• W2141338701 hasConcept C2779989193 @default.
• W2141338701 hasConcept C2780304432 @default.
• W2141338701 hasConcept C2781210498 @default.
• W2141338701 hasConcept C513476851 @default.
• W2141338701 hasConcept C535046627 @default.
• W2141338701 hasConcept C71924100 @default.
• W2141338701 hasConcept C98274493 @default.
• W2141338701 hasConceptScore W2141338701C126322002 @default.
• W2141338701 hasConceptScore W2141338701C137183658 @default.
• W2141338701 hasConceptScore W2141338701C197934379 @default.
• W2141338701 hasConceptScore W2141338701C2776750294 @default.
• W2141338701 hasConceptScore W2141338701C2778258207 @default.
• W2141338701 hasConceptScore W2141338701C2778375690 @default.
• W2141338701 hasConceptScore W2141338701C2779134260 @default.
• W2141338701 hasConceptScore W2141338701C2779424955 @default.
• W2141338701 hasConceptScore W2141338701C2779734285 @default.
• W2141338701 hasConceptScore W2141338701C2779989193 @default.
• W2141338701 hasConceptScore W2141338701C2780304432 @default.
• W2141338701 hasConceptScore W2141338701C2781210498 @default.
• W2141338701 hasConceptScore W2141338701C513476851 @default.
• W2141338701 hasConceptScore W2141338701C535046627 @default.
• W2141338701 hasConceptScore W2141338701C71924100 @default.
• W2141338701 hasConceptScore W2141338701C98274493 @default.
• W2141338701 hasIssue "2" @default.
• W2141338701 hasLocation W21413387011 @default.
• W2141338701 hasLocation W21413387012 @default.
• W2141338701 hasOpenAccess W2141338701 @default.
• W2141338701 hasPrimaryLocation W21413387011 @default.
• W2141338701 hasRelatedWork W140228277 @default.
• W2141338701 hasRelatedWork W1972563283 @default.
• W2141338701 hasRelatedWork W1986579279 @default.
• W2141338701 hasRelatedWork W2021763131 @default.
• W2141338701 hasRelatedWork W2071419048 @default.
• W2141338701 hasRelatedWork W2095044594 @default.
• W2141338701 hasRelatedWork W2102878073 @default.
• W2141338701 hasRelatedWork W2142359920 @default.
• W2141338701 hasRelatedWork W2615283617 @default.
• W2141338701 hasRelatedWork W2883372299 @default.
• W2141338701 hasVolume "41" @default.
• W2141338701 isParatext "false" @default.
• W2141338701 isRetracted "false" @default.
• W2141338701 magId "2141338701" @default.
• W2141338701 workType "article" @default.